Ecnoglutide: Research & Evidence
Emerging EvidencePublished research, clinical trial data, and evidence grading for Ecnoglutide across studied indications.
Back to Ecnoglutide overviewResearch Summary
Ecnoglutide has completed multiple Phase 3 trials primarily in Chinese populations. The EECOH-1 obesity trial (PMID: 40555243, published in Lancet Diabetes & Endocrinology 2025) demonstrated superior and sustained weight reduction vs placebo. A separate Phase 3 T2D trial showed superior HbA1c reduction at 0.6 mg and 1.2 mg once-weekly doses. The EECOH-2 trial compared ecnoglutide to dulaglutide over 52 weeks. DREAMS-1 provided head-to-head data vs semaglutide. Development has been focused on the China market through Sciwind Biosciences — no US FDA submission has been announced. The cAMP-biased mechanism is supported by preclinical data but clinical significance vs non-biased GLP-1 agonists is not yet established.
Evidence by Indication (2 indications)
| Indication | Tier | Trials | Summary |
|---|---|---|---|
| Obesity/weight loss | Tier B | 1 | Phase 3 RCT showed superior weight reduction vs placebo |
| Type 2 diabetes | Tier B | 2 | Phase 3 RCTs vs placebo and vs dulaglutide |
Graded using our evidence tier methodology.
Citations (2 sources)
- 1. Ecnoglutide for weight reduction in adults with overweight or obesity: Phase 3 trial Clinical Trial
Sciwind Biosciences Investigators (2025), Lancet Diabetes & Endocrinology
- 2. Ecnoglutide vs dulaglutide in Type 2 diabetes: 52-week Phase 3 trial (EECOH-2) Clinical Trial
Sciwind Biosciences Investigators (2025), Lancet Diabetes & Endocrinology